MMR vaccine explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:476995634
Type:combo
Component1:Measles vaccine
Class1:Vaccine
Component2:Mumps vaccine
Class2:Vaccine
Component3:Rubella vaccine
Class3:Vaccine
Tradename:M-M-R II, Priorix, Tresivac, others
Dailymedid:Measles
Pregnancy Au:B2
Pregnancy Au Comment:[1]
Atc Prefix:J07
Atc Suffix:BD52
Legal Au:S4
Legal Uk:POM
Legal Us:Rx-only
Legal Us Comment:[2] [3]
Legal Eu:Rx-only
Legal Eu Comment:[4]
Legal Status:Rx-only
Cas Number:1704518-68-2
Chemspiderid:None
Synonyms:MPR vaccine[5]

The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles), abbreviated as MMR. The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least four weeks between the doses.[6] [7] [8] After two doses, 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella.[6] The vaccine is also recommended for those who do not have evidence of immunity,[6] those with well-controlled HIV/AIDS,[9] [10] and within 72 hours of exposure to measles among those who are incompletely immunized.[7] It is given by injection.[11]

The MMR vaccine is widely used around the world. Worldwide over 500 million doses were administered between 1999 and 2004, and 575 million doses have been administered since the vaccine's introduction worldwide.[12] Measles resulted in 2.6 million deaths per year before immunization became common.[12] This has decreased to 122,000 deaths per year mostly in low-income countries.[12] Through vaccination,, rates of measles in North and South America are very low.[12] Rates of disease have been seen to increase in populations that go unvaccinated.[12] Between 2000 and 2018, vaccination decreased measles deaths by 73%.[13]

Side effects of immunization are generally mild and resolve without any specific treatment.[14] These may include fever, as well as pain or redness at the injection site.[14] Severe allergic reactions occur in about one in a million people.[14] Because it contains live viruses, the MMR vaccine is not recommended during pregnancy but may be given while breastfeeding.[6] The vaccine is safe to give at the same time as other vaccines.[14] Being recently immunized does not increase the risk of passing measles, mumps, or rubella on to others.[6] There is no evidence of an association between MMR immunisation and autistic spectrum disorders.[15] [16] [17] The MMR vaccine is a mixture of live weakened viruses of the three diseases.[6]

The MMR vaccine was developed by Maurice Hilleman.[18] It was licensed for use in the US by Merck in 1971. Stand-alone measles, mumps, and rubella vaccines had been previously licensed in 1963, 1967, and 1969, respectively.[19] [20] Recommendations for a second dose were introduced in 1989.[19] The MMRV vaccine, which also covers chickenpox, may be used instead.[6] An MR vaccine, without coverage for mumps, is also occasionally used.[21]

Medical use

Cochrane concluded that the "Existing evidence on the safety and effectiveness of MMR and MMRV vaccine supports current policies of mass immunisation aimed at global measles eradication in order to reduce morbidity and mortality associated with measles mumps rubella and varicella."

The combined MMR vaccine induces immunity less painfully than three separate injections at the same time, and sooner and more efficiently than three injections given on different dates. Public Health England reports that providing a single combined vaccine as of 1988, rather than giving the option to have them also done separately, increased uptake of the vaccine.[22]

Measles

Before the widespread use of a vaccine against measles, rates of disease were so high that infection was felt to be "as inevitable as death and taxes."[23] Reported cases of measles in the United States fell from hundreds of thousands to tens of thousands per year following introduction of the vaccine in 1963. Increasing uptake of the vaccine following outbreaks in 1971, and 1977, brought this down to thousands of cases per year in the 1980s. An outbreak of almost 30,000 cases in 1990 led to a renewed push for vaccination and the addition of a second vaccine to the recommended schedule. Fewer than 200 cases have been reported in the US each year between 1997 and 2013, and the disease is no longer considered endemic there.[24] [25] [26]

The benefit of measles vaccination in preventing illness, disability, and death has been well documented. The first 20 years of licensed measles vaccination in the US prevented an estimated 52 million cases of the disease, 17,400 cases of intellectual disability, and 5,200 deaths.[27] During 1999–2004, a strategy led by the World Health Organization and UNICEF led to improvements in measles vaccination coverage that averted an estimated 1.4 million measles deaths worldwide.[28] Between 2000 and 2018, measles vaccination resulted in a 73% decrease in deaths from the disease.

Measles is common in many areas of the world. Although it was declared eliminated from the US in 2000, high rates of vaccination and good communication with people who refuse vaccination are needed to prevent outbreaks and sustain the elimination of measles in the US. Of the 66 cases of measles reported in the US in 2005, slightly over half were attributable to one unvaccinated individual who acquired measles during a visit to Romania.[29] This individual returned to a community with many unvaccinated children. The resulting outbreak infected 34 people, mostly children and virtually all unvaccinated; 9% were hospitalized, and the cost of containing the outbreak was estimated at $167,685. A major epidemic was averted due to high rates of vaccination in the surrounding communities.[30]

In 2017, an outbreak of measles occurred among the Somali-American community in Minnesota, where MMR vaccination rates had declined due to the misconception that the vaccine could cause autism. The US Centers for Disease Control and Prevention recorded 65 affected children in the outbreak by April 2017.[31]

Rubella

Rubella, also known as German measles, was also very common before widespread vaccination. The major risk of rubella is during pregnancy when the baby may contract congenital rubella, which can cause significant congenital defects.[32]

Mumps

Mumps is another viral disease that was once very common, especially during childhood. If mumps is acquired by a male who is past puberty, a possible complication is bilateral orchitis, which can in some cases lead to sterility.[33]

Administration

The MMR vaccine is administered by a subcutaneous injection, the first dose typically at twelve months of age.[11] The second dose may be given as early as one month after the first dose. The second dose is a dose to produce immunity in the small number of persons (2–5%) who fail to develop measles immunity after the first dose. In the US it is done before entry to kindergarten because that is a convenient time.[34] Areas where measles is common typically recommend the first dose at nine months of age and the second dose at fifteen months of age.[7]

Safety

Adverse reactions, rarely serious, may occur from each component of the MMR vaccine. Ten percent of children develop fever, malaise, and a rash 5–21 days after the first vaccination;[35] and 3% develop joint pain lasting 18 days on average.[36] Older women appear to be more at risk of joint pain, acute arthritis, and even (rarely) chronic arthritis.[37] Anaphylaxis is an extremely rare but serious allergic reaction to the vaccine.[38] One cause can be egg allergy.[39] In 2014, the FDA approved two additional possible adverse events on the vaccination label: acute disseminated encephalomyelitis (ADEM), and transverse myelitis, with permission to also add "difficulty walking" to the package inserts.[40] A 2012 IOM report found that the measles component of the MMR vaccine can cause measles inclusion body encephalitis in immunocompromised individuals. This report also rejected any connection between the MMR vaccine and autism.[41] Some versions of the vaccine contain the antibiotic neomycin and therefore should not be used in people allergic to this antibiotic.[17]

The number of reports on neurological disorders is very small, other than evidence for an association between a form of the MMR vaccine containing the Urabe mumps strain and rare adverse events of aseptic meningitis, a form of viral meningitis.[37] [42] The UK National Health Service stopped using the Urabe mumps strain in the early 1990s due to cases of transient mild viral meningitis, and switched to a form using the Jeryl Lynn mumps strain instead.[43] The Urabe strain remains in use in a number of countries; MMR with the Urabe strain is much cheaper to manufacture than with the Jeryl Lynn strain,[44] and a strain with higher efficacy along with a somewhat higher rate of mild side effects may still have the advantage of reduced incidence of overall adverse events.[43]

A Cochrane review found that, compared with placebo, MMR vaccine was associated with fewer upper respiratory tract infections, more irritability, and a similar number of other adverse effects.

Naturally acquired measles often occurs with immune thrombocytopenic purpura (ITP, a purpuric rash and an increased tendency to bleed that resolves within two months in children), occurring in 1 to 20,000 cases. Approximately 1 in 40,000 children are thought to acquire ITP in the six weeks following an MMR vaccination. ITP below the age of six years is generally a mild disease, rarely having long-term consequences.[45] [46]

False claims about autism

See main article: MMR vaccine and autism.

In 1998 Andrew Wakefield et al. published a fraudulent paper about twelve children, reportedly with bowel symptoms and autism or other disorders acquired soon after administration of MMR vaccine,[47] while supporting a competing vaccine. In 2010, Wakefield's research was found by the General Medical Council to have been "dishonest",[48] and The Lancet fully retracted the paper.[49] [50] Three months following The Lancet's retraction, Wakefield was struck off the UK medical register, with a statement identifying deliberate falsification in the research published in The Lancet,[51] and was barred from practising medicine in the UK.[52] The research was declared fraudulent in 2011 by the British Medical Journal.[53]

Since Wakefield's publication, multiple peer-reviewed studies have failed to show any association between the vaccine and autism. The US Centers for Disease Control and Prevention,[54] [55] the Institute of Medicine of the US National Academy of Sciences,[56] the UK National Health Service[57] and the Cochrane Library review have all concluded that there is no evidence of a link.

Administering the vaccines in three separate doses does not reduce the chance of adverse effects, and it increases the opportunity for infection by the two diseases not immunized against first.[58] [59] Health experts have criticized media reporting of the MMR-autism controversy for triggering a decline in vaccination rates.[60] Before publication of Wakefield's article, the inoculation rate for MMR in the UK was 92%; after publication, the rate dropped to below 80%. In 1998, there were 56 measles cases in the UK; by 2008, there were 1348 cases, with two confirmed deaths.[61]

In Japan, the MMR triplet is not used. Immunity is achieved by a combination vaccine for measles and rubella, followed up later with a mumps only vaccine. This has had no effect on autism rates in the country, further disproving the MMR autism hypothesis.[62]

History

The component viral strains of MMR vaccine were developed by propagation in animal and human cells.[63]

For example, in the case of mumps and measles viruses, the virus strains were grown in embryonated chicken eggs. This produced strains of virus which were adapted for chicken cells and less well-suited for human cells. These strains are therefore called attenuated strains. They are sometimes referred to as neuroattenuated because these strains are less virulent to human neurons than the wild strains.

The Rubella component, Meruvax, was developed in 1967, through propagation using the human embryonic lung cell line WI-38 (named for the Wistar Institute) that was derived six years earlier in 1961.[64] [65]

Disease immunizedComponent vaccineVirus strainPropagation mediumGrowth medium
MeaslesAttenuvaxEnders' attenuated Edmonston strain[66] chick embryo cell cultureMedium 199
MumpsMumpsvax[67] Jeryl Lynn (B level) strain[68]
RubellaMeruvax IIWistar RA 27/3 strain of live attenuated rubella virusWI-38 human embryonic cell lineMEM (solution containing buffered salts, fetal bovine serum, human serum albumin and neomycin, etc.)
The term "MPR vaccine" is also used to refer to this vaccine, whereas "P" refer to parotitis which is caused by mumps.[5]

Merck MMR II is supplied freeze-dried (lyophilized) and contains live viruses. Before injection it is reconstituted with the solvent provided.[69]

According to a review published in 2018, the GlaxoSmithKline (GSK) MMR vaccine known as Pluserix "contains the Schwarz measles virus, the Jeryl Lynn–like mumps strain, and RA27/3 rubella virus".[70]

Pluserix was introduced in Hungary in 1999. Enders' Edmonston strain has been used since 1999 in Hungary in Merck MMR II product.[71] GSK Priorix vaccine, which uses attenuated Schwarz Measles, was introduced in Hungary in 2003.[71]

MMRV vaccine

See main article: MMRV vaccine.

The MMRV vaccine, a combined measles, mumps, rubella and varicella (chickenpox) vaccine, has been proposed as a replacement for the MMR vaccine to simplify administration of the vaccines.[72] Preliminary data indicate a rate of febrile seizures of 9 per 10,000 vaccinations with MMRV, as opposed to 4 per 10,000 for separate MMR and varicella shots; US health officials therefore do not express a preference for use of MMRV vaccine over separate injections.[73]

In a 2012 study[74] pediatricians and family doctors were sent a survey to gauge their awareness of the increased risk of febrile seizures (fever fits) in the MMRV. 74% of family doctors and 29% of pediatricians were unaware of the increased risk of febrile seizures. After reading an informational statement only 7% of family doctors and 20% of pediatricians would recommend the MMRV for a healthy 12- to 15-month-old child. The factor that was reported as the "most important" deciding factor in recommending the MMRV over the MMR+V was ACIP/AAFP/AAP recommendations (pediatricians, 77%; family physicians, 73%).

MR vaccine

This is a vaccine that covers measles and rubella but not mumps.[21] As of 2014, it was used in a "few (unidentified) countries".[21]

Society and culture

Religious concerns

Some brands of the vaccine use gelatin, derived from pigs, as a stabilizer. This has caused reduced take-up among some communities,[75] despite the fact that alternative vaccines without pig derivatives are approved and available.[76]

As the Rubella component of the Merck vaccine was developed using embryonic stem cell line WI-30 from an aborted fetus, the Pontifical Academy for Life has declared the development of the vaccine illicit and any other intention to create vaccines by means of aborted fetuses "formal cooperation in evil." The Pontifical Academy declared the use of vaccines by patients who do not share in the intention to create vaccines by abortion to be "very remote material cooperation" and morally licit to receive them if there are no alternative vaccines, given the proportional reason of preventing the spread of dangerous diseases. The Academy declared there remained a moral obligation to advocate for alternative vaccines and to use lawful means to oppose the creation of morally illicit vaccines by pharmaceutical companies and government groups.[77]

Further reading

Notes and References

  1. Web site: Measles virus vaccine / mumps virus vaccine / rubella virus vaccine (M-M-R II) Use During Pregnancy . Drugs.com . 16 October 2019 . 5 September 2020 . 12 November 2020 . https://web.archive.org/web/20201112003104/https://www.drugs.com/pregnancy/measles-virus-vaccine-mumps-virus-vaccine-rubella-virus-vaccine.html . live .
  2. Web site: M-M-R II- measles, mumps, and rubella virus vaccine live injection, powder, lyophilized, for suspension . DailyMed . 23 May 2022 . 19 June 2022 . 6 April 2020 . https://web.archive.org/web/20200406003823/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a9e384f-e717-436b-b9a0-15e53cef0862 . live .
  3. Web site: Priorix- measels, mumps, and rubella vaccine, live kit . DailyMed . 3 June 2022 . 19 June 2022 . 20 June 2022 . https://web.archive.org/web/20220620005258/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95c6fdb6-b587-4413-92f9-d592b9f7a23e . live .
  4. Web site: M-M-RVaxPro EPAR . . 17 September 2018 . 4 December 2020 . 6 April 2020 . https://web.archive.org/web/20200406174101/https://www.ema.europa.eu/en/medicines/human/EPAR/m-m-rvaxpro . live .
  5. Book: Grignolio A . Vaccines: Are they Worth a Shot? . 2018 . Springer . 9783319681061 . 2 . 22 May 2020 . 17 April 2021 . https://web.archive.org/web/20210417185159/https://books.google.com/books?id=hgFkDwAAQBAJ&pg=PA2 . live .
  6. Web site: Measles, Mumps, and Rubella (MMR) Vaccination: What Everyone Should Know . U.S. Centers for Disease Control and Prevention (CDC). 26 January 2021 . 26 April 2020 . https://web.archive.org/web/20200426105545/https://www.cdc.gov/vaccines/vpd/mmr/public/index.html . live .
  7. Measles vaccines: WHO position paper – April 2017 . Relevé Épidémiologique Hebdomadaire . 92 . 17 . 205–227 . April 2017 . 28459148 . 10665/255149 .
  8. Measles vaccines: WHO position paper, April 2017 - Recommendations . Vaccine . 37 . 2 . 219–222 . January 2019 . 28760612 . 10.1016/j.vaccine.2017.07.066 . 205605355 . World Health Organization .
  9. Web site: Kinney R . Core Concepts – Immunizations in Adults – Basic HIV Primary Care – National HIV CurriculumImmunizations in Adults . www.hiv.uw.edu . 2 May 2017 . 10 September 2018 . 2 September 2018 . https://web.archive.org/web/20180902191739/https://www.hiv.uw.edu/go/basic-primary-care/immunizations/core-concept/all . live .
  10. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L . [<!-- Official URL --> https://www.cdc.gov/mmwr/PDF/rr/rr4708.pdf Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP) ]. MMWR. Recommendations and Reports . 47 . RR-8 . 1–57 . May 1998 . 9639369 . 26 January 2020 . live . https://web.archive.org/web/20191030190011/https://www.cdc.gov/mmwr/PDF/rr/rr4708.pdf . 30 October 2019 .
  11. Web site: Administering MMR Vaccine . Centers for Disease Control and Prevention . 28 December 2021 . 26 January 2021 . 28 December 2021 . https://web.archive.org/web/20211228081247/https://www.cdc.gov/vaccines/vpd/mmr/hcp/administering-mmr.html . live .
  12. Web site: Addressing misconceptions on measles vaccination . European Centre for Disease Prevention and Control . 15 April 2014 . 10 September 2018 . 11 September 2018 . https://web.archive.org/web/20180911002527/https://ecdc.europa.eu/en/measles/prevention-and-control/addressing-misconceptions-measles . live .
  13. Web site: Measles Fact Sheet . World Health Organization (WHO) . 5 December 2019 . 28 November 2022 . 28 November 2022 . https://web.archive.org/web/20221128010546/https://www.who.int/en/news-room/fact-sheets/detail/measles . live .
  14. Web site: MMR (Measles, Mumps, and Rubella) Vaccine Information Statement . U.S. Centers for Disease Control and Prevention (CDC) . 16 August 2021 . August 2021 . 3 September 2018 . https://web.archive.org/web/20180903141726/https://www.cdc.gov/vaccines/hcp/vis/vis-statements/mmr.html . live .
  15. Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V . Vaccines for measles, mumps, rubella, and varicella in children . The Cochrane Database of Systematic Reviews . 2021 . 11 . CD004407 . November 2021 . 34806766 . 8607336 . 10.1002/14651858.CD004407.pub5 .
  16. Hussain A, Ali S, Ahmed M, Hussain S . The Anti-vaccination Movement: A Regression in Modern Medicine . Cureus . 10 . 7 . e2919 . July 2018 . 30186724 . 6122668 . 10.7759/cureus.2919 . free .
  17. Spencer JP, Trondsen Pawlowski RH, Thomas S . Vaccine Adverse Events: Separating Myth from Reality . American Family Physician . 95 . 12 . 786–794 . June 2017 . 28671426 .
  18. Maurice R. Hilleman, PhD, DSc . Seminars in Pediatric Infectious Diseases . 16 . 3 . 225–226 . July 2005 . 16044396 . 10.1053/j.spid.2005.05.002 .
  19. Goodson JL, Seward JF . Measles 50 Years After Use of Measles Vaccine . Infectious Disease Clinics of North America . 29 . 4 . 725–743 . December 2015 . 26610423 . 10.1016/j.idc.2015.08.001 .
  20. Web site: Measles: information about the disease and vaccines Questions and Answers . Immunization Action Coalition . November 2018 . 28 November 2022 . 28 November 2022 . https://web.archive.org/web/20221128011445/https://www.immunize.org/catg.d/p4209.pdf . live .
  21. Web site: Information Sheet Observed Rate of Vaccine Reactions, Measles, Mumps, and Rubella Vaccines . fdaghana.gov.gh . 30 April 2022 . May 2014 . 27 December 2021 . https://web.archive.org/web/20211227095245/https://fdaghana.gov.gh/img/vacine/MMR%20vaccine%20information.pdf . live .
  22. Web site: Measles, mumps, rubella (MMR): use of combined vaccine instead of single vaccines . GOV.UK . 12 July 2018 . 12 July 2018 . https://web.archive.org/web/20180712221642/https://www.gov.uk/government/publications/mmr-vaccine-dispelling-myths/measles-mumps-rubella-mmr-maintaining-uptake-of-vaccine . live .
  23. Babbott FL, Gordon JE . Modern measles . The American Journal of the Medical Sciences . 228 . 3 . 334–361 . September 1954 . 13197385 . 10.1097/00000441-195409000-00013 .
  24. [<!-- Official URL --> https://www.cdc.gov/mmwr/PDF/wk/mm4253.pdf Summary of notifiable diseases, United States, 1993 ]. MMWR. Morbidity and Mortality Weekly Report . 42 . 53 . i-xvii; 1–73 . October 1994 . 9247368 . 26 January 2020 . live . https://web.archive.org/web/20201024200449/https://www.cdc.gov/mmwr/PDF/wk/mm4253.pdf . 24 October 2020 . Centers for Disease Control and Prevention (CDC) .
  25. ((Centers for Disease Control and Prevention (CDC))) . [<!-- Official URL --> https://www.cdc.gov/mmwr/pdf/wk/mm5653.pdf Summary of Notifiable Diseases --- United States, 2007 ]. MMWR Morb. Mortal. Wkly. Rep. . 56 . 53 . July 2009 . 26 January 2020 . 24 October 2020 . https://web.archive.org/web/20201024200418/https://www.cdc.gov/mmwr/PDF/wk/mm5653.pdf . live .
  26. Book: U.S. Centers for Disease Control and Prevention (CDC) . Epidemiology and Prevention of Vaccine-Preventable Diseases . Hamborsky J, Kroger A, Wolfe S . 13th . Washington D.C. . 2015 . 978-0990449119 . 9 September 2017 . 30 December 2016 . https://web.archive.org/web/20161230001534/https://www.cdc.gov/vaccines/pubs/pinkbook/index.html . live .
  27. Bloch AB, Orenstein WA, Stetler HC, Wassilak SG, Amler RW, Bart KJ, Kirby CD, Hinman AR . Health impact of measles vaccination in the United States . Pediatrics . 76 . 4 . 524–532 . October 1985 . 3931045 . 10.1542/peds.76.4.524 . 6512947 .
  28. [<!-- Official URL --> https://www.cdc.gov/mmwr/pdf/wk/mm5509.pdf Progress in reducing global measles deaths, 1999-2004 ]. MMWR. Morbidity and Mortality Weekly Report . 55 . 9 . 247–249 . March 2006 . 16528234 . 26 January 2020 . live . https://web.archive.org/web/20210305135803/https://www.cdc.gov/mmwr/pdf/wk/mm5509.pdf . 5 March 2021 . Centers for Disease Control and Prevention (CDC) .
  29. [<!-- Official URL --> https://www.cdc.gov/mmwr/pdf/wk/mm5550.pdf Measles--United States, 2005 ]. MMWR. Morbidity and Mortality Weekly Report . 55 . 50 . 1348–1351 . December 2006 . 17183226 . 26 January 2020 . live . https://web.archive.org/web/20210126050729/https://www.cdc.gov/mmwr/PDF/wk/mm5550.pdf . 26 January 2021 . Centers for Disease Control and Prevention (CDC) .
  30. Parker AA, Staggs W, Dayan GH, Ortega-Sánchez IR, Rota PA, Lowe L, Boardman P, Teclaw R, Graves C, LeBaron CW . Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States . The New England Journal of Medicine . 355 . 5 . 447–455 . August 2006 . 16885548 . 10.1056/NEJMoa060775 . 34529542 . free .
  31. Hall V, Banerjee E, Kenyon C, Strain A, Griffith J, Como-Sabetti K, Heath J, Bahta L, Martin K, McMahon M, Johnson D, Roddy M, Dunn D, Ehresmann K . [<!-- Official URL --> https://www.cdc.gov/mmwr/volumes/66/wr/pdfs/mm6627.pdf Measles Outbreak - Minnesota April-May 2017 ]. MMWR. Morbidity and Mortality Weekly Report . 66 . 27 . 713–717 . July 2017 . 28704350 . 5687591 . 10.15585/mmwr.mm6627a1 . 26 January 2020 . live . https://web.archive.org/web/20200802231920/https://www.cdc.gov/mmwr/volumes/66/wr/pdfs/mm6627.pdf . 2 August 2020 .
  32. Web site: Measles, Mumps, Rubella (MMR) Vaccine and Immunization Information . National Network for Immunization Information (NNii) . 22 April 2010 . 28 November 2022 . https://web.archive.org/web/20221128012158/https://www.immunizationinfo.org/vaccines/rubella/ . 28 November 2022 . live .
  33. Book: Male infertility: a guide for the clinician. Jequier AM. 978-0-632-05129-8. Malden, MA. Blackwell Publishing. 2000. 118. 24 September 2016. 17 April 2021. https://web.archive.org/web/20210417193726/https://books.google.com/books?id=ULWh1Wc1nKMC. live.
  34. Web site: MMR vaccine questions and answers . 2004 . 28 May 2008 . U.S. Centers for Disease Control and Prevention (CDC) . dead . https://web.archive.org/web/20080725232358/http://www.cdc.gov/vaccines/vpd-vac/combo-vaccines/mmr/faqs-mmr-hcp.htm . 25 July 2008 .
  35. Harnden A, Shakespeare J . 10-minute consultation: MMR immunisation . BMJ . 323 . 7303 . 32 . July 2001 . 11440943 . 1120664 . 10.1136/bmj.323.7303.32 .
  36. Thompson GR, Ferreyra A, Brackett RG . Acute arthritis complicating rubella vaccination . Arthritis and Rheumatism . 14 . 1 . 19–26 . 1971 . 5100638 . 10.1002/art.1780140104 . 1 September 2019 . live . free . 25 November 2011 . https://web.archive.org/web/20111125081635/http://deepblue.lib.umich.edu/bitstream/2027.42/37715/1/1780140104_ftp.pdf . 2027.42/37715 .
  37. Schattner A . Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines . Vaccine . 23 . 30 . 3876–3886 . June 2005 . 15917108 . 10.1016/j.vaccine.2005.03.005 .
  38. Carapetis JR, Curtis N, Royle J . MMR immunisation. True anaphylaxis to MMR vaccine is extremely rare . BMJ . 323 . 7317 . 869 . October 2001 . 11683165 . 1121404 . 10.1136/bmj.323.7317.869a .
  39. Fox A, Lack G . Egg allergy and MMR vaccination . The British Journal of General Practice . 53 . 495 . 801–802 . October 2003 . 14601358 . 1314715 . dead . https://archive.today/20130126182439/http://openurl.ingenta.com/content/nlm?genre=article&issn=0960-1643&volume=53&issue=495&spage=801&aulast=Fox . 26 January 2013 .
  40. Web site: Approval for label change. Food and Drug Administration. https://web.archive.org/web/20150203162448/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm394905.htm . 3 February 2015 .
  41. Book: Stratton K, Ford A, Rusch E, Clayton EW . ((Institute of Medicine)) . Adverse Effects of Vaccines . 2012 . 24624471 . 10.17226/13164 . 978-0-309-21435-3 . . Bookshelf ID: NBK190024 . Washington, D.C. .
  42. Book: Stratton KR, Howe CJ, Johnston RB . Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality . 1994 . 978-0-309-07496-4 . Measles and mumps vaccines . http://books.nap.edu/openbook.php?record_id=2138&page=131 . . ((Institute of Medicine)) . 10.17226/2138 . 25144097 . Bookshelf ID: NBK236291 . 29 August 2007 . 24 August 2015 . https://web.archive.org/web/20150824183227/http://books.nap.edu/openbook.php?record_id=2138&page=131 . live .
  43. Colville A, Pugh S, Miller E . Withdrawal of a mumps vaccine . European Journal of Pediatrics . 153 . 6 . 467–468 . June 1994 . 8088305 . 10.1007/BF01983415 . 43300463 .
  44. Fullerton KE, Reef SE . Commentary: Ongoing debate over the safety of the different mumps vaccine strains impacts mumps disease control . International Journal of Epidemiology . 31 . 5 . 983–984 . October 2002 . 12435772 . 10.1093/ije/31.5.983 . free .
  45. Sauvé LJ, Scheifele D . Do childhood vaccines cause thrombocytopenia? . Paediatrics & Child Health . 14 . 1 . 31–32 . January 2009 . 19436461 . 2661332 . 10.1093/pch/14.1.31 .
  46. Black C, Kaye JA, Jick H . MMR vaccine and idiopathic thrombocytopaenic purpura . British Journal of Clinical Pharmacology . 55 . 1 . 107–111 . January 2003 . 12534647 . 1884189 . 10.1046/j.1365-2125.2003.01790.x .
  47. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA . Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children . Lancet . 351 . 9103 . 637–641 . February 1998 . 9500320 . 10.1016/S0140-6736(97)11096-0 . 5 September 2007 . live . 439791 . https://web.archive.org/web/20070927010149/http://briandeer.com/mmr/lancet-paper.htm . 27 September 2007 .
  48. News: Jardine C . GMC brands Dr Andrew Wakefield 'dishonest, irresponsible and callous'. https://ghostarchive.org/archive/20220112/https://www.telegraph.co.uk/news/health/7095145/GMC-brands-Dr-Andrew-Wakefield-dishonest-irresponsible-and-callous.html . 12 January 2022 . subscription . live. 31 January 2015. The Telegraph. 29 January 2010. London.
  49. Retraction—Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children . Lancet . 375 . 9713 . 445 . February 2010 . 20137807 . 10.1016/S0140-6736(10)60175-4 . 26364726 .
  50. News: Triggle N . Lancet accepts MMR study 'false' . BBC News . 2 February 2010 . 11 June 2022 . 3 November 2021 . https://web.archive.org/web/20211103171340/http://news.bbc.co.uk/2/hi/health/8493753.stm . live .
  51. Web site: General Medical Council, Fitness to Practise Panel Hearing, 24 May 2010, Andrew Wakefield, Determination of Serious Professional Misconduct . 18 September 2011 . General Medical Council . dead . https://web.archive.org/web/20110809092833/http://www.gmc-uk.org/Wakefield_SPM_and_SANCTION.pdf_32595267.pdf . 9 August 2011 .
  52. News: MMR row doctor Andrew Wakefield struck off register . The Guardian. 24 May 2010. 24 May 2010 . London . Meikle J, Sarah B . https://web.archive.org/web/20100527003931/http://www.guardian.co.uk/society/2010/may/24/mmr-doctor-andrew-wakefield-struck-off. 27 May 2010 . live .
  53. Godlee F, Smith J, Marcovitch H . Wakefield's article linking MMR vaccine and autism was fraudulent . BMJ . 342 . jan05 1; c7452 . c7452 . January 2011 . 21209060 . 10.1136/bmj.c7452 . 43640126 .
  54. Web site: Measles, Mumps, Rubella (MMR) Vaccine . U.S. Centers for Disease Control and Prevention (CDC) . 24 August 2018 . 28 November 2022 . https://web.archive.org/web/20221128012741/https://www.cdc.gov/vaccinesafety/vaccines/mmr-vaccine.html . 28 November 2022.
  55. Web site: Autism and Vaccines - Vaccine Safety . U.S. Centers for Disease Control and Prevention (CDC) . 24 August 2018 . 28 November 2022 . https://web.archive.org/web/20221128012758/https://www.cdc.gov/vaccinesafety/concerns/autism.html . 28 November 2022 . live .
  56. Book: ((Institute of Medicine)) . Immunization Safety Review . . Washington, D.C. . 2004 . 978-0-309-09237-1 . 10.17226/10997 . Bookshelf ID: NBK25344 . 20669467 . free . doi .
  57. Web site: MMR (measles, mumps and rubella) vaccine . . 4 July 2022 . 28 November 2022 . https://web.archive.org/web/20221128013700/https://www.nhs.uk/conditions/vaccinations/mmr-vaccine/ . 28 November 2022 . live .
  58. Web site: MMR: myths and truths . 3 September 2007 . 2004 . National Health Service . dead . https://web.archive.org/web/20080913173824/http://www.mmrthefacts.nhs.uk/basics/truths.php . 13 September 2008 .
  59. MMR vs three separate vaccines:
    • Halsey NA, Hyman SL . Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000 . Pediatrics . 107 . 5 . E84 . May 2001 . 11331734 . 10.1542/peds.107.5.e84 . Conference Writing Panel . free . doi .
    • Leitch R, Halsey N, Hyman SL . MMR--Separate administration-has it been done? . Pediatrics . 109 . 1 . 172 . January 2002 . 11773568 . 10.1542/peds.109.1.172 . Letter to the editor .
    • Miller E . MMR vaccine: review of benefits and risks . The Journal of Infection . 44 . 1 . 1–6 . January 2002 . 11972410 . 10.1053/jinf.2001.0930 .
  60. News: Doctors issue plea over MMR jab . BBC News . 4 February 2009 . 26 June 2006 . 7 July 2018 . https://web.archive.org/web/20180707192022/http://news.bbc.co.uk/2/hi/health/5118166.stm . live .
  61. Thomas J . 2010 . Paranoia strikes deep: MMR vaccine and autism . https://archive.today/20150409124829/http://www.searchmedica.com/resource.html?rurl=http://www.psychiatrictimes.com/display/article/10168/1531916 . live . 9 April 2015 . Psychiatric Times . 27 . 3 . 1–6 .
  62. Honda H, Shimizu Y, Rutter M . No effect of MMR withdrawal on the incidence of autism: a total population study . Journal of Child Psychology and Psychiatry, and Allied Disciplines . 46 . 6 . 572–579 . June 2005 . 15877763 . 10.1111/j.1469-7610.2005.01425.x . 10253998 . 10.1.1.579.1619 .
  63. Wellington K, Goa KL . Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella . Drugs . 63 . 19 . 2107–26 . 2003 . 12962524 . 10.2165/00003495-200363190-00012 .
  64. Plotkin SA, Vaheri A . Human fibroblasts infected with rubella virus produce a growth inhibitor . Science . 156 . 3775 . 659–661 . May 1967 . 6023662 . 10.1126/science.156.3775.659 . 32622296 . 1967Sci...156..659P .
  65. Hayflick L, Moorhead PS . The serial cultivation of human diploid cell strains . Experimental Cell Research . 25 . 3 . 585–621 . December 1961 . 13905658 . 10.1016/0014-4827(61)90192-6 .
  66. Web site: Attenuvax Product Sheet. 4 February 2009. 2006. Merck & Co. 1. https://web.archive.org/web/20091231032205/http://merck.com/product/usa/pi_circulars/a/attenuvax/attenuvax_pi.pdf. 31 December 2009.
  67. Web site: MUMPSVAX (Mumps Virus Vaccine Live) Jeryl Lynn Strain. https://web.archive.org/web/20060813175920/http://www.merck.com/product/usa/pi_circulars/m/mumpsvax/mumpsvax_pi.pdf. 13 August 2006. dead. 2002. Merck Co.. Merck Co.. Merck & Co.. 26 January 2015.
  68. Young ML, Dickstein B, Weibel RE, Stokes J, Buynak EB, Hilleman MR . Experiences with Jeryl Lynn strain live attenuated mumps virus vaccine in a pediatric outpatient clinic . Pediatrics . 40 . 5 . 798–803 . November 1967 . 6075651 . 10.1542/peds.40.5.798 . 35878536 .
  69. Web site: About the Vaccine – MMR and MMRV Vaccine Composition and Dosage. 7 October 2021. 26 January 2021. U.S. Centers for Disease Control and Prevention (CDC) . 6 October 2021. https://web.archive.org/web/20211006025435/https://www.cdc.gov/vaccines/vpd/mmr/hcp/about.html. live.
  70. Book: 10.1016/B978-0-323-35761-6.00052-3. Rubella Vaccines. Plotkin's Vaccines. 2018. Reef SE, Plotkin SA . 970–1000.e18. 9780323357616.
  71. Böröcz K, Csizmadia Z, Markovics Á, Farkas N, Najbauer J, Berki T, Németh P . Application of a fast and cost-effective 'three-in-one' MMR ELISA as a tool for surveying anti-MMR humoral immunity: the Hungarian experience . Epidemiology and Infection . 148 . e17 . February 2020 . 32014073 . 7019553 . 10.1017/S0950268819002280 .
  72. Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A . Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine . The Pediatric Infectious Disease Journal . 26 . 7 . 632–638 . July 2007 . 17596807 . 10.1097/INF.0b013e3180616c8f . 41981427 .
  73. [<!-- Official URL --> https://www.cdc.gov/mmwr/PDF/wk/mm5710.pdf Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine ]. MMWR. Morbidity and Mortality Weekly Report . 57 . 10 . 258–260 . March 2008 . 18340332 . 26 January 2020 . live . https://web.archive.org/web/20201019154628/https://www.cdc.gov/mmwr/PDF/wk/mm5710.pdf . 19 October 2020 . Centers for Disease Control and Prevention (CDC) . Advisory Committee on Immunization Practices (ACIP) .
  74. O'Leary ST, Suh CA, Marin M . Febrile seizures and measles-mumps-rubella-varicella (MMRV) vaccine: what do primary care physicians think? . Vaccine . 30 . 48 . 6731–6733 . November 2012 . 22975026 . 10.1016/j.vaccine.2012.08.075 .
  75. News: Pager T . 'Monkey, Rat and Pig DNA': How Misinformation Is Driving the Measles Outbreak Among Ultra-Orthodox Jews . 14 April 2019 . . 9 April 2019 . 14 April 2019 . https://web.archive.org/web/20190414053524/https://www.nytimes.com/2019/04/09/nyregion/jews-measles-vaccination.html . live .
  76. Web site: Vaccines and porcine gelatine . . 14 April 2019 . August 2015 . 14 April 2019 . https://web.archive.org/web/20190414103713/https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/751199/Vaccines_porcine_gelatine.pdf . live .
  77. Pontifical Academy for Life Statement: Moral Reflections on Vaccines Prepared from Cells Derived from Aborted Human Foetuses. Linacre Q. 2019 May;86(2-3):182-187. doi: 10.1177/0024363919855896. Epub 2019 Aug 13. PMID: 32431408; PMCID: PMC6699053.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "MMR vaccine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.